Emerging Digital Trends in Virology Software: Optimizing Viral Discovery, Surveillance,and Patient Management.

Notice

This is an unedited manuscript accepted for publication and provided as an Article in Press for early access at the author’s request. The article will undergo copyediting, typesetting, and galley proof review before final publication. Please be aware that errors may be identified during production that could affect the content. All legal disclaimers of the journal apply.

Year : 2026 | Volume : 3 | 01 | Page :
    By

    Mohd. Wasiullah,

  • Piyush Yadav,

  • Aman Kumar Maurya,

  1. Principal, Department of Pharmacy, Prasad Institute of Technology, Jaunpur (U.P.), India
  2. Head, Department of Pharmaceutical Chemistry, Prasad Institute of Technology, Jaunpur (U.P.), India
  3. Scholar, Department of Pharmacy, Prasad Institute of Technology, Jaunpur (U.P.), India

Abstract

Virology and antiviral therapeutics are being reshaped by rapid advances in computational tools, automation platforms, and virus-focused digital health applications. Software systems now span the entire virology value chain, from in silico viral target identification and antigen design, to AI-supported clinical trial management for vaccines and antivirals, to post-marketing pharmacovigilance and patient-facing mobile tools. This review examines current and emerging software trends relevant to virus studies, emphasizing applications in viral discovery, molecular modeling, high-throughput screening, real-world evidence (RWE) for viral diseases, and digital support for infected or at-risk populations. Particular attention is given to artificial intelligence (AI), machine learning (ML), cloud computing, and integrated virology data ecosystems that enable faster response to outbreaks, improved vaccine and antiviral development, and more precise patient monitoring. The article concludes with a discussion of future opportunities and challenges around interoperability, ethical AI, cybersecurity, and human-AI collaboration within virus research and viral disease management.

Keywords: Virology software; Viral genomics; Antiviral drug discovery; Vaccine informatics; Digital health; Artificial intelligence; Machine learning; Real-world evidence; Pharma 4.0; Viral surveillance

How to cite this article:
Mohd. Wasiullah, Piyush Yadav, Aman Kumar Maurya. Emerging Digital Trends in Virology Software: Optimizing Viral Discovery, Surveillance,and Patient Management.. International Journal of Virus Studies. 2026; 03(01):-.
How to cite this URL:
Mohd. Wasiullah, Piyush Yadav, Aman Kumar Maurya. Emerging Digital Trends in Virology Software: Optimizing Viral Discovery, Surveillance,and Patient Management.. International Journal of Virus Studies. 2026; 03(01):-. Available from: https://journals.stmjournals.com/ijvs/article=2026/view=237724


References

1. Schneider G. Automating drug discovery. Nat Rev Drug Discov. 2018;17(2):97–113. 2. Lusher SJ, McGuire R, Van Schaik RC. Data-driven drug discovery: opportunities and challenges. Drug Discov Today. 2021;26(6):1604–1612. 3. Zhavoronkov A. Artificial intelligence in drug discovery and development. Nat Biotechnol. 2020;38(6):685–688. 4. Walters WP, Barzilay R. Applications of artificial intelligence in pharmaceutical sciences. Trends Pharmacol Sci. 2021;42(10):821–833. 5. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477. 6. Jiménez-Luna J, Grisoni F, Wenzel J, Schneider G. Artificial intelligence in drug discovery: recent advances and future perspectives. Nat Rev Drug Discov. 2021;20(9):697–715. 7. Sarker F, Jadhav A, Gohil S, et al. Digitalization in pharmaceutical manufacturing: a review. Pharmaceutics. 2022;14(3):512. 8. Lee SL, O’Connor TF, Yang X, Cruz CN, Chatterjee S, Madurawe RD, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Sci. 2015;104(3):775–785. 9. Khin NA, et al. Regulatory perspectives on artificial intelligence and machine learning in drug development. Clin Pharmacol Ther. 2022;111(4):778–781. 10. Horgan D, et al. Digital health in personalized medicine: a new era of patient care. Biomed Pharmacother. 2021;141:111821. 11. Lofts FJ, et al. Cloud computing and the evolution of pharmaceutical informatics. Drug Discov Today. 2020;25(7):1216–1223. 12. Martin JH, et al. Data-driven clinical trials: AI integration in patient selection. Nat Rev Clin Oncol. 2022;19(6):367–379. 13. Chee YJ, et al. Remote monitoring and digital therapeutics: a pharma perspective. Front Digit Health. 2023;5:104512. 14. Kirchhoff CF, et al. Pharma 4.0 and smart manufacturing. ISPE J. 2021;11(1):1–9. 15. AbuJarour J, et al. Automation in R&D laboratories. Lab Chip. 2022;22(4):789–804. 16. Topol EJ. Deep medicine: artificial intelligence and the future of healthcare. Nat Med. 2019;25(1):44–56. 17. Senanayake P, et al. Digital twins in pharmaceutical manufacturing. Comput Chem Eng. 2023;177:108369. 18. Jurewicz M, et al. Regulatory challenges in pharmaceutical AI applications. Pharmaceutics. 2022;14(5):1023. 19. Harish S, et al. Integration of blockchain in pharma supply chains. Front Blockchain. 2023;6:118765. 20. Gohil S, et al. Pharmaceutical data management and cybersecurity. Comput Struct Biotech Nol J. 2021;19:2385–2396. 21. Park S, et al. Quantum computing in drug discovery. Chem Rev. 2023;123(2):1025–1062. 22. Cao Y, et al. Generative AI in molecular design. Chem Soc Rev. 2023;52(4):1234–1258. 23. Chatterjee A, et al. Robotics and automation in pharmaceutical research. Adv Drug Deliv Rev. 2023;197:114832. 24. Bansal S, et al. Artificial intelligence in pharmacovigilance: current applications and challenges. Drug Saf. 2022;45(3):241–252. 25. Dubey P, et al. Predictive maintenance and digital twins: an industrial perspective. IEEE Trans Ind Inform. 2023;19(5):3214–3224. 26. U.S. Food and Drug Administration. Artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan. Silver Spring (MD): U.S. Food and Drug Administration; 2021. 27. European Medicines Agency. Guideline on computerised systems and electronic data in clinical trials. Amsterdam: European Medicines Agency; 2023. 28. International Society for Pharmaceutical Engineering. ISPE Pharma 4.0 maturity model: guidance document. North Bethesda (MD): ISPE; 2021. 29. International Society for Pharmaceutical Engineering. GAMP 5: a risk-based approach to compliant GxP computerized systems. 2nd ed. North Bethesda (MD): ISPE; 2022. 30. Holliday ZM, et al. Digital health data ecosystems and interoperability. NPJ Digit Med. 2023;6(1):12. 31. Rumsfeld JS, et al. Digital transformation of health systems. JAMA. 2022;328(10):913–914. 32. Singh R, et al. Sustainable and green digital pharmaceutical systems. Environ Sci Technol. 2024;58(7):4123–4135. 33. Gupta V, et al. Integration of AI and robotics in pharmaceutical quality control. Eur J Pharm Sci. 2022;176:106256. 34. Huang Y, et al. Data-driven optimization in continuous pharmaceutical manufacturing. Comput Chem Eng. 2023;169:108020. 35. Geris L, et al. Human–AI collaboration in drug development. Nat Rev Drug Discov. 2023;22(5):345–362. 36. Bock C, et al. Real-world evidence in pharmaceutical innovation. Clin Pharmacol Ther. 2020;107(1):40–44. 37. Ekins S, et al. Computational toxicology and software integration. Chem Res Toxicol. 2022;35(4):567–580. 38. Chakraborty S, et al. AI-assisted regulatory compliance in pharmaceuticals. Front Pharmacol. 2023;14:118945. 39. Clarke J, et al. Ethical AI in pharmaceuticals: governance and bias control. Nat Mach Intell. 2022;4(3):201–210. 40. Rangwala H, et al. Future trends in pharmaceutical data science. Drug Discov Today. 2024;29(1):103–115. 41. Park S, et al. Quantum computing in drug discovery. Chem Rev. 2023;123(2):1025–1062. 42. Cao Y, et al. Generative AI in molecular design. Chem Soc Rev. 2023;52(4):1234–1258. 43. Chatterjee A, et al. Robotics and automation in pharmaceutical research. Adv Drug Deliv Rev. 2023;197:114832. 44. Bansal S, et al. Artificial intelligence in pharmacovigilance: current applications and challenges. Drug Saf. 2022;45(3):241–252. 45. Dubey P, et al. Predictive maintenance and digital twins: an industrial perspective. IEEE Trans Ind Inform. 2023;19(5):3214–3224. 46. U.S. Food and Drug Administration. Artificial intelligence/machine learning (AI/ML)-based software as a medical device (SaMD) action plan. Silver Spring (MD): U.S. Food and Drug Administration; 2021. 47. European Medicines Agency. Guideline on computerised systems and electronic data in clinical trials. Amsterdam: European Medicines Agency; 2023. 48. International Society for Pharmaceutical Engineering. ISPE Pharma 4.0 maturity model: guidance document. North Bethesda (MD): ISPE; 2021. 49. International Society for Pharmaceutical Engineering. GAMP 5: a risk-based approach to compliant GxP computerized systems. 2nd ed. North Bethesda (MD): ISPE; 2022. 50. Holliday ZM, et al. Digital health data ecosystems and interoperability. NPJ Digit Med. 2023;6(1):12. 51. Rumsfeld JS, et al. Digital transformation of health systems. JAMA. 2022;328(10):913–914. 52. Singh R, et al. Sustainable and green digital pharmaceutical systems. Environ Sci Technol. 2024;58(7):4123–4135. 53. Gupta V, et al. Integration of artificial intelligence and robotics in pharmaceutical quality control. Eur J Pharm Sci. 2022;176:106256. 54. Huang Y, et al. Data-driven optimization in continuous pharmaceutical manufacturing. Comput Chem Eng. 2023;169:108020. 55. Geris L, et al. Human–AI collaboration in drug development. Nat Rev Drug Discov. 2023;22(5):345–362. 56. Bock C, et al. Real-world evidence in pharmaceutical innovation. Clin Pharmacol Ther. 2020;107(1):40–44. 57. Ekins S, et al. Computational toxicology and software integration. Chem Res Toxicol. 2022;35(4):567–580. 58. Chakraborty S, et al. AI-assisted regulatory compliance in pharmaceuticals. Front Pharmacol. 2023;14:118945. 59. Clarke J, et al. Ethical AI in pharmaceuticals: governance and bias control. Nat Mach Intell. 2022;4(3):201–210. 60. Rangwala H, et al. Future trends in pharmaceutical data science. Drug Discov Today. 2024;29(1):103–115. 61. Horgan D, et al. Digital health in personalized medicine: a new era of patient care. Biomed Pharmacother. 2021;141:111821. 62. Chee YJ, et al. Remote monitoring and digital therapeutics: a pharmaceutical perspective. Front Digit Health. 2023;5:104512. 63. Topol EJ. Deep medicine: artificial intelligence and the future of healthcare. Nat Med. 2019;25(1):44–56. 64. Martin JH, et al. Data-driven clinical trials: artificial intelligence integration in patient selection. Nat Rev Clin Oncol. 2022;19(6):367–379. 65. Bansal S, et al. Artificial intelligence in pharmacovigilance: current applications and challenges. Drug Saf. 2022;45(3):241–252. 66. Vamathevan J, Clark D, Czodrowski P, Dunham I, Ferran E, Lee G, et al. Applications of machine learning in drug discovery and development. Nat Rev Drug Discov. 2019;18(6):463–477. 67. Horgan D, et al. Digital health in personalized medicine: a new era of patient care. Biomed Pharmacother. 2021;141:111821. 68. Topol EJ. Deep medicine: artificial intelligence and the future of healthcare. Nat Med. 2019;25(1):44–56. 69. Chee YJ, et al. Remote monitoring and digital therapeutics: a pharmaceutical perspective. Front Digit Health. 2023;5:104512. 70. Rumsfeld JS, et al. Digital transformation of health systems. JAMA. 2022;328(10):913–914. 71. U.S. Food and Drug Administration. Artificial Intelligence/Machine Learning (AI/ML)-Based Software as a Medical Device (SaMD) Action Plan. Silver Spring (MD): U.S. Food and Drug Administration; 2021. 72. European Medicines Agency. Guideline on computerised systems and electronic data in clinical trials. Amsterdam: European Medicines Agency; 2023. 73. Gohil S, et al. Pharmaceutical data management and cybersecurity. Comput Struct Biotechnol J. 2021;19:2385–2396. 74. Clarke J, et al. Ethical AI in pharmaceuticals: governance and bias control. Nat Mach Intell. 2022;4(3):201–210. 75. Gohil S, et al. Pharmaceutical data management and cybersecurity. Comput Struct Biotechnol J. 2021;19:2385–2396. 76. Harish S, et al. Integration of blockchain in pharmaceutical supply chains. Front Blockchain. 2023;6:118765. 77. Rangwala H, et al. Future trends in pharmaceutical data science. Drug Discov Today. 2024;29(1):103–115. 78. Geris L, et al. Human–AI collaboration in drug development. Nat Rev Drug Discov. 2023;22(5):345–362. 79. Geris L, et al. Human–AI collaboration in drug development. Nat Rev Drug Discov. 2023;22(5):345–362. 80. Rangwala H, et al. Future trends in pharmaceutical data science. Drug Discov Today. 2024;29(1):103–115. 81. Park S, et al. Quantum computing in drug discovery. Chem Rev. 2023;123(2):1025–1062. 82. Cao Y, et al. Generative artificial intelligence in molecular design. Chem Soc Rev. 2023;52(4):1234–1258. 83. Chatterjee A, et al. Robotics and automation in pharmaceutical research. Adv Drug Deliv Rev. 2023;197:114832. 84. AbuJarour J, et al. Automation in research and development laboratories. Lab Chip. 2022;22(4):789–804. 85. Senanayake P, et al. Digital twins in pharmaceutical manufacturing. Comput Chem Eng. 2023;177:108369. 86. Dubey P, et al. Predictive maintenance and digital twins: an industrial perspective. IEEE Trans Ind Inform. 2023;19(5):3214–3224. 87. Holliday ZM, et al. Digital health data ecosystems and interoperability. NPJ Digit Med. 2023;6(1):12. 88. Lofts FJ, et al. Cloud computing and the evolution of pharmaceutical informatics. Drug Discov Today. 2020;25(7):1216–1223. 89. Singh R, et al. Sustainable and green digital pharmaceutical systems. Environ Sci Technol. 2024;58(7):4123–4135. 90. Huang Y, et al. Data-driven optimization in continuous pharmaceutical manufacturing. Comput Chem Eng. 2023;169:108020.

Ahead of Print Subscription Review Article
Volume 03
01
Received 03/02/2026
Accepted 04/02/2026
Published 20/02/2026
Publication Time 17 Days
62

Login


My IP

PlumX Metrics